Drugs & TargetsFree Cabometyx sNDA receives FDA priority review for previously treated radioactive iodine-refractory differentiated thyroid cancer August 06, 2021Vol.47 No.31
Drugs & TargetsFree BMS issues statement on Istodax relapsed/refractory peripheral T-cell lymphoma U.S. indication August 06, 2021Vol.47 No.31
Drugs & TargetsFree Keytruda receives FDA approval for high-risk early-stage TNBC July 30, 2021Vol.47 No.30
Drugs & TargetsFree FDA issues alert about increased risk of death associated with Pepaxto July 30, 2021Vol.47 No.30
Drugs & Targets Keytruda + Lenvima receive FDA approval for advanced endometrial carcinoma July 23, 2021Vol.47 No.29
Drugs & Targets Rezurock receives FDA approval for chronic graft-versus-host disease July 23, 2021Vol.47 No.29
Drugs & Targets Venclexta + azacitidine receive breakthrough therapy designation from FDA for myelodysplastic syndromes July 23, 2021Vol.47 No.29
Drugs & Targets Darzalex Faspro + pomalidomide and dexamethasone receives FDA approval for multiple myeloma July 16, 2021Vol.47 No.28
Drugs & Targets Padcev receives regular approval from FDA for locally advanced or metastatic urothelial cancer July 16, 2021Vol.47 No.28
